Deadline for Execution by Licensee. If this Patent & Technology License Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within thirty (30) days of the date of signature set forth under the Licensor’s signature below, then this Patent & Technology License Agreement shall be null and void and of no further effect.
Deadline for Execution by Licensee. If the Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 within 30 days of the date of signature set forth under the Licensor’s signature below, then the Agreement shall be null and void and of no further effect.
Deadline for Execution by Licensee. If University executes this Agreement first and Licensee fails to execute and return it to University within 30 days of the date of University’s signature below, then the Agreement is null and void. THE PARTIES HEREBY EXECUTE THIS AGREEMENT Regents of the University of Minnesota Insert name of Licensee here By: By: Insert name of signatory Its: Insert title of signatory Technology Commercialization Insert name of signatory Its: Insert title of signatory Date: Date: The signatory warrants that they are authorized to execute this agreement on behalf of the Regents of the University of Minnesota. The signatory warrants that they are authorized to execute this agreement on behalf of Licensee GENERAL TERMS DEFINITIONS AND INTERPRETATION Definitions In this Agreement:
Deadline for Execution by Licensee. If University executes this Agreement first and Licensee fails to execute and return it to University within 30 days of the date of University’s signature below, then the Agreement is null and void.
Deadline for Execution by Licensee. If this Patent License Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within 30 days of the date of signature set forth under the Licensor’s signature below, then this Patent License Agreement shall be null and void and of no further effect. [***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. Licensee: AEMase Inc. CONFIDENTIAL Exclusive PLA IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Patent License Agreement. LICENSOR: THE UNIVERSITY OF TEXAS AT AUSTIN ON BEHALF OF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM LICENSEE: AEMase Inc. By /s/ Xxxxxx X. Xxxxx By /s/ Xxxxx X. Xxxx Xxxxxx X. Xxxxx, X.X. Xxxxx X. Xxxx Associate Vice President for Research and Director, Office of Technology Commercialization President and Chief Executive Officer Date 12/20/13 Date 12/24/13 [***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. Licensee: AEMase Inc. CONFIDENTIAL Exclusive PLA EXHIBIT A
Deadline for Execution by Licensee. [18] If University executes this Agreement first and Licensee fails to execute and return it to the University within 30 days of the date of University’s signature below, then the Agreement is null and void. [18] This provision prevents the licensee from delaying entry into agreement and keeping university from potentially licensing to third parties. THE PARTIES HEREBY EXECUTE THIS AGREEMENT Regents of the University of [State] Insert name of Licensee here By: By: Insert name of signatory Its: Insert title of signatory Office for Technology Commercialization Insert name of signatory Its: Insert title of signatory Date: Date: The signatory warrants that they are authorized to execute this agreement on behalf of the Regents of the University of [State]. The signatory warrants that they are authorized to execute this agreement on behalf of Licensee GENERAL TERMS Terms Annotations
Deadline for Execution by Licensee. If this PTLA is executed first by a Party (the “Initiating party”) and is not executed by the other Party and received by the Initiating Party at the address and in the manner set forth in Section 18 of the Terms and Conditions within sixty (60) days of the date of signature set forth under the Initiating Party’s signature below, then this PTLA shall be null and void and of no further effect.
Deadline for Execution by Licensee. If this PTLA is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within thirty (30) days of the date of signature set forth under the Licensor’s signature below, then this PTLA shall be null and void and of no further effect. {00258124-1}Licensee: Arno Therapeutics, Inc. CONFIDENTIAL Exclusive License (Non-Equity) INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Deadline for Execution by Licensee. If this PTLA is executed first by a Party (the “Initiating party”) and is not executed by the other Party and received by the Initiating Party at the address and in the manner set forth in Section 18 of the Terms and Conditions within sixty (60) days of the date of signature set forth under the Initiating Party’s signature below, then this PTLA shall be null and void and of no further effect. [***] Licensee: Cellectis CONFIDENTIAL Exclusive License (Life Sciences) [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this PTLA. LICENSOR: OHIO STATE INNOVATION FOUNDATION LICENSEE: Cellectis SA BY: /s/ Xxxx Xxxxxx BY: /s/ Xxxxx XXXXXXXX Name: Xxxx Xxxxxx NAME: Xxxxx XXXXXXXX Title: Vice President TITLE: Chief Executive Officer DATE: 23 October 2014 DATE: October 15, 2014 [***] Licensee: Cellectis CONFIDENTIAL Exclusive License (Life Sciences) [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. EXHIBIT A TERMS AND CONDITIONS OF THE PTLA These Terms and Conditions of the PTLA (“Terms and Conditions”) are incorporated by reference into the PTLA to which they are attached. All Section references in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise.
Deadline for Execution by Licensee. If this Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in paragraph 10.1 of the Agreement within 30 days of the date of signature set forth under the Licensor's signature below, then this Agreement shall be null and void and of no further effect. The Parties have caused this Agreement to become effective as of the date last executed below. LICENSEE: VG LIFE SCIENCES, INC. LICENSOR: XXXXX & WHITE HEALTHCARE /s/ Xxxx Xxxxxxxxx /s/ Xxxxxx X. Xxxxx By: Xxxx Xxxxxxxxx Xxxxxx X. Xxxxx, M.D. Title: President President/CEO Date: 7/6/2013 Date: 7/18/2013
